| Code | CSB-RA001950MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Anselamimab, targeting the amyloid precursor protein (APP). APP is a transmembrane glycoprotein that plays crucial roles in neuronal development, synaptic plasticity, and iron export. Sequential proteolytic cleavage of APP by β-secretase and γ-secretase generates amyloid-beta peptides, which aggregate to form the characteristic plaques found in Alzheimer's disease. Dysregulation of APP processing is central to the amyloidogenic pathway implicated in neurodegeneration, making it a critical target for understanding disease mechanisms and therapeutic development.
Anselamimab represents a therapeutic antibody approach designed to modulate APP processing and reduce amyloid-beta production. This biosimilar antibody provides researchers with a valuable tool for investigating APP biology, studying amyloid cascade mechanisms, and exploring potential interventions in neurodegenerative disease models. It enables examination of APP-related pathways in cellular and molecular studies, supporting research into Alzheimer's disease pathogenesis and the evaluation of amyloid-targeting strategies in preclinical settings.
There are currently no reviews for this product.